Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease

Marehbian, Josh; Arrighi, H Michael; Hass, Steve; Tian, Haijun; Sandborn, William J
October 2009
American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2524
Academic Journal
OBJECTIVES:We sought to determine whether treatment with steroids, immunosuppressives (ISs), and anti-tumor necrosis factor (TNF) agents is associated with an increased risk of adverse events in patients with Crohn's disease (CD).METHODS:This study analyzed claims from patients with CD and controls without CD from the United States with private insurance (2002–2005). Patients were classified by treatment with steroids, ISs, anti-TNF agents, combinations of two or three, and none of these medications. Follow-up adverse events in patients with CD and controls were compared across different treatment categories and are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Within the CD patients, a subset analysis examined the relationship between therapies and outcomes.RESULTS:A total of 22,310 patients with CD (8,581 longitudinal cohort cases) and 111,550 controls were identified. Compared with the controls, CD patients had higher rate ratios for all pre-specified events. Within the CD patient population subgroup, monotherapy with steroids, ISs, or anti-TNF agents was associated with an increased risk of tuberculosis (TB) (HR 2.7; 95% CI, 1.0–7.3), candidiasis (HR 2.7; 95% CI, 1.8–4.0), herpes zoster (HR 1.7; 95% CI, 1.0–2.7), sepsis (HR 1.3; 95% CI, 1.1–1.5), demyelinating conditions (HR 3.2; 95% CI, 1.5–6.9), and cervical dysplasia (HR 1.5; 95% CI, 1.2–2.0) as compared with patients not receiving these medications. The use of two or three of these medications further increased these risks: TB (HR 7.4; 95% CI, 2.1–26.3), candidiasis (HR 3.8; 95% CI, 2.0–7.6), herpes zoster (HR 3.7; 95% CI, 1.8–7.5), sepsis (HR 1.6; 95% CI, 1.2–2.1), and cervical dysplasia (HR 1.8; 95% CI, 1.1–3.0).CONCLUSIONS:Treatment with steroids, ISs, or anti-TNF agents singly and in combination in patients with CD is associated with increased risks of infection, demyelinating disorders, and cervical dysplasia.


Related Articles

  • Management of Varicella Infection During the Course of Inflammatory Bowel Disease. Mouzas, I. A.; Greenstein, A. J.; Giannadaki, E.; Balasubramanian, S.; Manousos, O. N.; Sachar, D. B. // American Journal of Gastroenterology;Sep1997, Vol. 92 Issue 9, p1534 

    Objective: To study the natural history and outcome of varicella infection developing in steroid treated inflammatory bowel disease. Background: Varicella infection occurring in immunosuppressed or immunocompromised patients is a common problem with a significant mortality. Varicella infection...

  • How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease. Culver, Emma L.; Travis, Simon P. L. // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p198 

    The advent of biological therapy has had a significant impact on the management of patients with inflammatory bowel disease. Nevertheless, anti-TNF-alpha agents are still used with caution, driven by concerns about the risk of infection. Stringent post-marketing surveillance programmes and...

  • Is There an Increased Risk of Lymphoma and Malignancies Under Anti-TNF Therapy in IBD? Lakatos, P. L.; Miheller, P. // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p179 

    Tumour necrosis factor alpha (TNF-alpha) inhibitors ensure valuable treatment advantages for patients with inflammatory bowel diseases (IBD) by offering a more targeted anti-inflammatory therapy. In contrast, there is concern that it might increase the risk of long-term complications including...

  • Anti-TNF Antibody Therapy for Inflammatory Bowel Disease During Pregnancy: A Clinical Review. Mourabet, Marwa El; El-Hachem, Sandra; Harrison, Janet R.; Binio, David G. // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p234 

    The incidence of inflammatory bowel disease (IBD; Crohn's disease, ulcerative colitis) is highest during the peak reproductive years, hence the increased concern with the safety of IBD drugs during pregnancy. Over the past 11 years, anti-TNF-a antibody therapy has emerged as a treatment approach...

  • Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. Mosli, Mahmoud H; Sandborn, William J; Kim, Richard B; Khanna, Reena; Al-Judaibi, Bandar; Feagan, Brian G // American Journal of Gastroenterology;Jul2014, Vol. 109 Issue 7, p994 

    The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model. Modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk...

  • Effects of Age at Disease Onset and at Treatment on Serology in Inflammatory Bowel Diseases. Pellino, Gianluca // Digestive Diseases & Sciences;Jan2015, Vol. 60 Issue 1, p278 

    No abstract available.

  • De novo Crohn's post Liver Transplantation: A rare case. Srinivasan, Sridhar // Internet Journal of Gastroenterology;2008, Vol. 6 Issue 2, p1 

    Immunosuppressive therapy is well established for treating inflammatory bowel disease (IBD). However we present a patient who developed IBD while on sufficient immunosupression.

  • Methotrexate Induces Clinical and Histologic Remission in Patients with Refractory Inflammatory Bowel Disease. Kozarek, Richard A.; Patterson, David J.; Gelfand, Martin D.; Botoman, V. Alin; BAll, Terrence J.; Wilske, Kenneth R. // Annals of Internal Medicine;3/1/89, Vol. 110 Issue 5, p353 

    Presents a study which investigated the effects of methotrexate in patients with refractory inflammatory bowel disease. Factors which limit the application of immunosuppressive agents azathioprine and 6-mercaptopurine in the treatment of refractory inflammatory bowel disease; Types of diseases...

  • Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis. Nguyen, Douglas; Nguyen, Emily; Bechtold, Matthew // Digestive Diseases & Sciences;Aug2015, Vol. 60 Issue 8, p2446 

    Background: Several studies have evaluated the effect of immunosuppressive therapy for the treatment of inflammatory bowel disease (IBD) on response to routine vaccinations. The overall effect of specific classes of medications (i.e., immunomodulator vs. biologics) on vaccine response remains...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics